Glecaprevir + Pibrentasvir

Kathryn Dzintars, Pharm.D., BCPS
Glecaprevir + Pibrentasvir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of adult patients with chronic HCV infection (genotypes 1, 2, 3, 4, 5, or 6) without cirrhosis or compensated cirrhosis (Child-Pugh A).
  • Treatment of adult patients with HCV Genotype 1 infection previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Treatment of adult patients with chronic HCV infection (genotypes 1, 2, 3, 4, 5, or 6) without cirrhosis or compensated cirrhosis (Child-Pugh A).
  • Treatment of adult patients with HCV Genotype 1 infection previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

There's more to see -- the rest of this entry is available only to subscribers.